Together with the reverse merger, Candid Therapeutics introduced $505 million in non-public financing to help its pipeline of T cell engagers for autoimmune illness. Lead program cizutamig is on observe to start world Part 2 testing in myasthenia gravis and interstitial lung illness.
The put up Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline appeared first on MedCity Information.
